NCT02458014View on ClinicalTrials.gov

Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 14, 2015

Primary Completion Date

September 16, 2025

Study Completion Date

September 16, 2025

Conditions
Adult Acute Lymphoblastic Leukemia in Complete RemissionB Acute Lymphoblastic LeukemiaMinimal Residual DiseasePhiladelphia Chromosome Positive
Interventions
BIOLOGICAL

Blinatumomab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02458014 - Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease | Biotech Hunter | Biotech Hunter